Proteomic Analysis of Blood Plasma using High Throughput Sequencers

使用高通量测序仪对血浆进行蛋白质组学分析

• 批准号: 10009883
• 负责人: Mark Patrick McPike
• 金额: $ 94.07万
• 依托单位: APTAMATRIX, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10009883
• 关键词: Aptamer Technology; Ascites; Binding; Bioinformatics; Biological Assay; Biological Markers; Blood; Budgets; Cancer Burden; Cancer Diagnostics; Cancer Patient; Chemicals; Clinic; Clinical; Clinical Research; Computer software; Custom; DNA; DNA Sequence; DNA sequencing; Data; Databases; Death Rate; Detection; Diagnosis; Diagnostic; Disease; Engineering; Evolution; Freeze Drying; Goals; Growth; Health; Health Care Research; Human; Image; Individual; Laboratory Research; Lead; Libraries; Liquid substance; Machine Learning; Magnetic Resonance Imaging; Malignant Neoplasms; Malignant neoplasm of prostate; Mass Spectrum Analysis; Measurement; Measures; Medical; Methods; Modification; Monitor; New York; Nucleic Acids; Oncology; Outcome; Output; Patients; Pharmaceutical Preparations; Phase; Physicians; Physicians' Offices; Physiological; Plasma; Plasma Proteins; Pleural; Population; Prevention; Prostate Cancer therapy; Proteins; Proteome; Proteomics; Protocols documentation; Publishing; Quality of life; RNA; Radiation therapy; Reagent; Research; Research Personnel; Sampling; Scientist; Screening for Prostate Cancer; Societies; Software Tools; Source; Stream; Surveys; Techniques; Technology; Testing; Therapeutic; Therapeutic Intervention; Universities; Urine; aptamer; base; cancer therapy; cancer type; chemotherapy; cost; effective therapy; healthy volunteer; human subject; individual patient; individualized medicine; instrument; liquid biopsy; predicting response; primary endpoint; protein biomarkers; protein profiling; research clinical testing; success; targeted treatment; tool; treatment risk; tumor

Abstract Aptamers made from DNA, RNA and other nucleic acids that have chemical modifications can be engineered to bind tightly to biomolecules like the proteins that circulate in blood. The primary goal of this project is to develop a kit of aptamer reagents to enable simultaneous measurement of protein abundance profiles, focusing especially on significant differentially abundant proteins in blood. This will aid in cancer diagnostics and in monitoring protein populations over the course of disease and therapeutic intervention. The intended product is an Aptamer Proteomics kit (AP-kit) that can be used by researchers and clinicians to comprehensively profile the differences between healthy individuals and those afflicted with cancer. The kits will be validated in-house and tested with carefully curated samples focused on prostate cancer. The AP-kits will give cancer scientists new tools that lead to breakthroughs in the understanding of cancer types and to create new and more effective treatments and preventions. Physicians will be enabled to diagnose tumors earlier, reducing the burden of radiation treatments and chemotherapy on cancer patients. AP-assays will aid in monitoring the progress of cancer therapies and allow treatments to be customized for individual patients. These outcomes will increase quality of life and substantially decrease the burden of cancer on society.

摘要 由DNA、RNA和其他具有化学修饰的核酸制成的适体可以被工程化 与血液中循环的蛋白质等生物分子紧密结合。 本项目的主要目标是开发一套适体试剂盒，以实现同步测量 的蛋白质丰度谱，特别侧重于显着差异丰富的蛋白质在血液中。这 将有助于癌症诊断和监测疾病和治疗过程中的蛋白质群体， 干预预期产品是适体蛋白质组学试剂盒（AP试剂盒），可供研究人员使用， 临床医生全面描绘健康个体和癌症患者之间的差异。 这些试剂盒将在内部进行验证，并使用专注于前列腺癌的精心策划的样本进行测试。 AP-kit将为癌症科学家提供新的工具，从而在理解癌症方面取得突破 并创造新的和更有效的治疗和预防。医生将能够诊断 癌症患者可以更早地治疗肿瘤，减轻放射治疗和化疗对癌症患者的负担。AP测定 将有助于监测癌症治疗的进展，并允许为个人定制治疗。 患者这些结果将提高生活质量，并大大减少癌症对社会的负担。